Bristol-Myers Squibb Company
업데이트됨

Bristol will fall an extra 10%

132
BMY has reported somewhat disappointing results for 2025, and the investors' disappointment is evident in the breakdown of the double top that had formed.

This suggests a likely drop of about 10% in the stock price, although it doesn't affect the long term. The weaker sales in generic drugs should be offset by additional cost reductions, but nobody likes holding stocks that rely on cutting costs...

We suggest a short-term sell to take advantage of this 10% drop and then wait to see how BMY's price reacts.
거래청산: 스탑 닿음
A fake breakout happened, this is a bull signal that moved the price to the opposite side of the channel.

면책사항

해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.